PF-Atlas › Clinical Trials › NCT02919995

A Study of RPL554 in Patients With Cystic Fibrosis

RPL554 · Phase 2

Registry ID

NCT02919995

Phase

Phase 2

Status

Completed

Drug / intervention

RPL554

Sponsor

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA

Start

2017-02-08

About this trial

RPL554 is evaluated in NCT02919995, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA. Current status: Completed.

View NCT02919995 on ClinicalTrials.gov →

Explore related

All RPL554 trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT02919995 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.